The clinical-stage pharmaceutical company SOM Biotech, focused in repositioning drugs in orphan CNS indications, has just closed a €2M euros financing round led by investor from a Monaco based private investment firm.

Dr. Raúl Insa, SOM Biotech CEO, will be presenting the company at MABA (Mid-Atlantic Bio Angels) Forum. This event will take place in New York (US) on December 13th. Further information at http://bioangels.net/index.php

Dr. Raúl Insa, SOM Biotech CEO, will be one of the speakers at next B-Debate on 'Drug Repurposing for Rare Diseases. The Cure for the 21st Century'. Barcelona 17th and 18th November 2016. Further information at B-Debate Barcelona

SOM Biotech will attend next BIO-Europe, Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. It is regarded as a “must attend” event for the biotech industry. This event will take place in Cologne from 7-9 November 2016.…

Dr. Raúl Insa, SOM Biotech CEO, will be one of the speakers at the 4th International Congress on Research & Innovation in Neurodegenerative Diseases. This relevant event will take place at the EU Intellectual Property Office (EUIPO) in Alicante, Spain, from September 21-23, 2016. More than one hundred national and international experts will discuss the major advances in the…

SOM Biotech and the Anglo-Italian biotech accelerator Inorgen (www.inorgen.com) have successfully reached an agreement to co-develop drug repositioning programs focused mainly on rare diseases. Repositioning and rare diseases are two concepts widely known by both companies. By combining these concepts, costs and time needed to bring the drug onto the market is reduced. Safety risks are…